Yayın dışı

Gelişen haber · 1 haber

FDA panel review of seven unapproved peptides

İlk yayın En son yayın

GelişiyorSonraki kontrol : The committee’s recommendations on whether pharmacies may compound and dispense the seven peptides.

Son durum

The FDA Pharmacy Compounding Advisory Committee began its two-day review of seven unapproved peptides on July 23. FDA career scientists recommended against compounding all seven, citing a lack of human clinical data for three and inadequate data for the others; the committee’s recommendations have not yet been reported.

Haber takibi1. gün

1 haber11 yayın organı11 kaynak1 video

  • Henüz tarihli olay yok
    1. 1. güncellemeSix Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record

    Şimdiye kadarki gelişmeler

    1. 1. güncelleme

      Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record

      A two-day meeting in Washington ended with a narrow recommendation to loosen compounding rules for unapproved compounds championed by influencers and RFK Jr. — over the objections of the agency's own staff.

      Bu haberden sonra hâlâ yanıtsız

      • Whether the FDA will adopt the committee's recommendation in full or in part.
      • Which specific peptides failed to win a majority, given the gap between seven on the agenda and six (or four) endorsed.

    Geçmiş

    1. Açıldı1 haber

    Kimler dahil

    Kişiler

    • Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 haber
    • Robert F. Kennedy Jr.26th United States Secretary of Health and Human Services since 20251 haber

    Yerler

    • ChinaChina1 haber
    • WashingtonWashington, DC, USA1 haber

    Bu haberle ilgili okuduğumuz tüm yayın organları

    11 kaynak11 yayın organı1 video